Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Eniluracil and Surgery in Treating Patients With Primary or Metastatic Colorectal Cancer

ABSTRACT: RATIONALE: Eniluracil may increase the effectiveness of chemotherapy by blocking tumor enzymes that break down chemotherapy drugs. PURPOSE: Randomized phase II trial to determine the effectiveness of eniluracil followed by surgery in treating patients who have primary or metastatic colorectal cancer.

DISEASE(S): Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2003609 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

Enhancing therapeutic efficacy through degradation of endogenous extracellular matrix in primary breast tumor spheroids.

Project description:Cancer remains the leading cause of death globally, with nearly 20 million new cases and 10 million fatalities in 2022. The majority (90%) are solid tumors, which are strongly influenced by the tumor microenvironment (TME)—a complex network of blood vessels, connective tissues, immune cells, and the extracellular matrix (ECM). The ECM, rich in collagen, fibronectin, elastin, and laminin, is constantly remodelled, driving tumor progression and drug resistance while increasing tissue stiffness. Breast cancer, the most common malignancy in women, causes 500,000 deaths annually. Its ECM, particularly collagen composition, varies depending on tumor type and prognosis. Recent research has emphasized 3D tumor spheroid models, which replicate in vivo tumor conditions better than traditional 2D cultures. These models allow more accurate drug testing and better understanding of tumor biology. To improve treatment, researchers have developed a 3D breast cancer spheroid model using rat-derived primary cells with an endogenous ECM structure. By applying collagenases to break down ECM barriers, they demonstrated that ECM degradation enhances drug penetration and chemotherapy effectiveness. This study highlights the critical role of ECM in cancer progression and treatment resistance. Targeting the ECM within advanced 3D models could improve therapeutic outcomes and lead to more effective anticancer strategies.

2025-07-14 | PXD061082 | Pride

Portal Vein Embolization in Treating Patients With Liver Metastases From Primary Colorectal Cancer

Project description:RATIONALE: Embolization blocks blood flow to part of an organ and/or tumor. Blocking the portal vein on one side of the liver may cause the opposite side of the liver to increase in size and decrease the risk of liver failure following surgery. PURPOSE: Phase II trial to study the effectiveness of portal vein embolization in treating patients who have liver metastases from primary colorectal cancer.

| 2007016 | ecrin-mdr-crc

Genome wide analysis of Suv4-20h1/2 depleted animal caps [dataset4]

Project description:Suv4-20h1/2 are histone methyltransferases that write the H4K20me2 and H4K20me3 marks. We knocked down these enzymes using translation blocking morpholinos in X. tropicalis animal caps and performed RNA-seq in order to investigate the impact of altering H4K20me state on epidermal differentiation. Knocking down Suv4-20h1/2 leads to a strong increase of H4K20me1 in bulk chromatin. To determine whether increased H4K20me1 is responsible for transcriptional changes in suv4-20h KD animal caps, we performed RNA-Seq for a rescue experiment with PHF8, an H4K20me1 demethylase.

2021-09-01 | GSE161250 | GEO

Genome wide analysis of Suv4-20h1/2 depleted animal caps [dataset3]

2021-09-01 | GSE161249 | GEO

Genome wide analysis of Suv4-20h1/2 depleted animal caps [dataset2]

2021-09-01 | GSE161248 | GEO

Genome wide analysis of Suv4-20h1/2 depleted animal caps [dataset1]

2021-09-01 | GSE161247 | GEO

Project description:Roots break down soil microbes

| PRJNA1202878 | ENA

BCX-1777 in Treating Patients With Refractory Cancer

Project description:RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.

| 2010182 | ecrin-mdr-crc

Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer

Project description:RATIONALE: Bortezomib may interfere with the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who have metastatic or recurrent colorectal cancer.

| 2008702 | ecrin-mdr-crc

Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer

Project description:RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Combining erlotinib with combination chemotherapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining erlotinib with oxaliplatin, leucovorin, and fluorouracil in treating patients who have metastatic colorectal cancer.

| 2008458 | ecrin-mdr-crc

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data